Викторианское правительство запустило программу грантов до $1 млн для разработки мРНК-вакцин

Deadline: 07-Sep-2026 The mRNA Victoria Pipeline Program – Round 1 provides grants of up to $1 million to eligible Victorian organisations developing innovative mRNA vaccines and therapeutics. The program supports projects moving promising pre-clinical candidates toward GMP manufacturing and Phase I clinical trials, helping strengthen Victoria’s sovereign mRNA research, development, commercialisation, and biomanufacturing capabilities. What Is the mRNA Victoria Pipeline Program? The mRNA Victoria Pipeline Program – Round 1 is a Victorian Government funding initiative designed to accelerate the development and commercialisation of innovative messenger RNA (mRNA) vaccines and therapeutics. The program aims to strengthen Victoria’s sovereign mRNA capability by helping promising research projects progress from pre-clinical development toward clinical development and manufacturing. The funding supports the broader development of Victoria as a centre for: - Advanced medical research - mRNA technology - Vaccine development - Therapeutic development - Biomanufacturing - Clinical translation - Commercialisation The program focuses on turning promising scientific discoveries into products that can ultimately progress toward clinical trials and market development. Why Does the mRNA Victoria Program Matter? mRNA technology has become an important platform for developing new vaccines and therapeutic treatments. However, moving an innovative mRNA candidate from laboratory research into clinical development requires significant investment, technical expertise, regulatory preparation, manufacturing capability, and commercial planning. The Pipeline Program is designed to address these development challenges by supporting projects that can move toward: Pre-clinical research → Proof of concept → Product development → GMP manufacturing → Phase I clinical development This can help reduce the gap between scientific research and commercial or clinical application. What Types of Projects Are Supported? The program supports innovative mRNA-based vaccines and therapeutics. mRNA Vaccines Eligible projects can include the development of mRNA vaccines for: The focus is on innovative vaccine candidates with potential to progress toward clinical development. mRNA Therapeutics The program can also support mRNA therapeutics targeting areas such as: - Cancer - Genetic disorders - Rare diseases - Autoimmune diseases Applicants should demonstrate the scientific and commercial potential of the proposed therapeutic approach. What Activities Can the Grant Support? Funding can support activities across the development pathway. Pre-Clinical Proof-of-Concept Studies Funding may support research needed to establish whether an mRNA candidate works as intended before entering clinical development. This can include relevant pre-clinical testing and validation activities. Safety Testing Projects may include studies required to evaluate the safety and suitability of the candidate for further development. Prototype Production Funding can support the development and production of prototypes needed to advance the mRNA vaccine or therapeutic. Manufacturing Readiness Projects should be capable of progressing toward Good Manufacturing Practice (GMP) manufacturing. GMP refers to quality and manufacturing standards used for products intended for clinical use. Regulatory Readiness Funding can support activities that prepare the candidate for regulatory requirements and future clinical development. Commercialisation Planning Applicants can use funding for activities that strengthen the commercial pathway of the technology. This may include: - Commercialisation planning - Market development - Business planning - Intellectual property strategy - Industry engagement - Development planning Specialist Equipment Eligible projects may include the acquisition of specialist equipment required to advance the mRNA development programme. Commercialisation Training and Upskilling The program can also support training and upskilling in commercialisation, helping researchers and organisations develop the skills needed to translate scientific discoveries into commercially viable products. How Much Funding Is Available? The mRNA Victoria Pipeline Program – Round 1 offers grants of up to $1 million per eligible project. The funding is intended to support significant development activities that can move an mRNA candidate toward clinical and manufacturing readiness. Applicants should demonstrate that the requested funding is directly connected to the proposed development activities and expected outcomes. Who Is Eligible? The program is intended for Victorian-based organisations developing relevant mRNA technologies. Eligible organisation types include: - Companies registered under the Corporations Act 2001 (Cth) - Incorporated associations established under Victorian legislation - Statutory corporations - Universities - Hospitals - TAFEs - Other eligible Victorian organisations meeting the program requirements Victorian Connection Requirement Applicants must have a qualifying connection to Victoria. An organisation must: - Hold an Australian Business Number (ABN). - Operate from Victoria, or - Be headquartered in Victoria, or - Have a Victorian subsidiary. Applicants should clearly demonstrate their Victorian presence and how the proposed project contributes to Victoria’s mRNA capability. Intellectual Property Requirements Applicants must hold the relevant intellectual property (IP) or have appropriate rights to commercialise the technology. This is an important eligibility requirement because the program is designed to support technologies with a pathway toward development and commercialisation. Applicants should therefore be able to demonstrate: - Ownership of relevant IP, or - Appropriate commercialisation rights. - A clear pathway for using the technology. - The ability to develop and commercialise the proposed product. Manufacturing Requirement Projects must be capable of being manufactured at the BioNTech GMP Clinical Manufacturing Facility or R&D Production Laboratory. This requirement means applicants need to consider manufacturing feasibility when developing their project proposal. The proposed technology should have a realistic pathway toward manufacturing at the relevant facility. Technology Readiness Level Requirement Projects must be capable of progressing to a higher Technology Readiness Level (TRL) within three years. Technology Readiness Levels are used to describe how mature a technology is, ranging from early-stage research to technologies that are demonstrated and ready for practical or commercial application. Applicants should clearly explain: - The current maturity of the technology. - The project’s current TRL. - The target TRL. - Activities required to reach the next stage. - How grant funding will accelerate this progression. - What can realistically be achieved within three years. Co-Funding and Financial Capacity Applicants must demonstrate either: - Appropriate co-funding, or - Sufficient financial capacity to complete the project beyond the grant support. The grant is therefore not intended to be the sole source of funding for projects where additional resources are necessary for completion. Applicants should demonstrate that they have a credible financial plan for taking the project beyond the funded activities. How the Program Can Accelerate mRNA Development The funding can help organisations overcome important development barriers. A typical development pathway could involve: Stage 1: Scientific Validation Researchers establish proof of concept and demonstrate that the mRNA candidate has potential. Stage 2: Pre-Clinical Development The candidate undergoes appropriate safety and efficacy-related testing. Stage 3: Product Development The organisation develops a suitable prototype and establishes relevant technical processes. Stage 4: Manufacturing Preparation The project moves toward manufacturing under appropriate GMP conditions. Stage 5: Regulatory Preparation The organisation prepares the documentation, processes, and evidence needed for future regulatory engagement. Stage 6: Clinical Development The longer-term objective is to position suitable candidates for progression toward Phase I clinical trials. What Is GMP Manufacturing? Good Manufacturing Practice (GMP) refers to quality standards and controlled manufacturing processes used to ensure that products intended for human use are consistently produced to appropriate quality standards. For mRNA vaccines and therapeutics, manufacturing readiness is an important step between laboratory development and clinical testing. The program’s manufacturing requirement ensures that supported projects have a credible pathway toward clinical-grade production. What Is a Phase I Clinical Trial? A Phase I clinical trial is an early-stage clinical study generally focused on evaluating the safety, tolerability, and appropriate characteristics of a new medical intervention in humans. The Pipeline Program is intended to help promising pre-clinical candidates move toward this stage. What Makes a Strong Application? A strong proposal should demonstrate both scientific potential and a credible development pathway. Applicants should clearly explain: - The scientific innovation. - The disease or health challenge being addressed. - The current development stage. - Existing proof-of-concept evidence. - The proposed development activities. - The expected technical outcomes. - The manufacturing pathway. - The regulatory pathway. - The commercialisation strategy. - The project’s expected TRL progression. - The role of the Victorian mRNA ecosystem. - The financial resources available beyond the grant. How to Prepare an Application Step 1: Confirm Organisational Eligibility Check that your organisation: - Is eligible under the program. - Has an ABN. - Has an appropriate Victorian connection. - Meets the relevant legal requirements. Step 2: Confirm the Technology Is Eligible Ensure that your project involves an innovative mRNA vaccine or therapeutic within the supported disease and research areas. Step 3: Establish Your IP Position Demonstrate that your organisation owns the relevant IP or has the legal rights necessary to commercialise the technology. Step 4: Define the Development Gap Clearly identify what is preventing the candidate from progressing to the next development stage. For example: - Additional pre-clinical validation. - Safety testing. - Prototype development. - Manufacturing development. - Regulatory preparation. - Commercialisation planning. Step 5: Develop a Three-Year Development Pathway Explain how the project will increase its Technology Readiness Level within three years. Include: - Current technology maturity. - Development activities. - Milestones. - Target TRL. - Expected outputs. - Longer-term clinical development pathway. Step 6: Address Manufacturing Explain how the proposed product can be manufactured through the BioNTech GMP Clinical Manufacturing Facility or R&D Production Laboratory. Step 7: Develop the Financial Plan Prepare a realistic project budget and demonstrate co-funding or sufficient financial capacity to complete the project beyond the grant period. Step 8: Explain Commercialisation Show how the project could move from research and development toward commercial or clinical application. Common Mistakes to Avoid Applicants should avoid: - Proposing technologies that are not mRNA-based. - Failing to demonstrate a Victorian organisational connection. - Not providing evidence of IP ownership or commercialisation rights. - Presenting a project with no clear development pathway. - Providing insufficient evidence of pre-clinical potential. - Ignoring the GMP manufacturing requirement. - Failing to explain the target Technology Readiness Level. - Proposing milestones that cannot realistically be achieved within three years. - Treating the grant as the only required source of funding. - Providing a weak commercialisation strategy. - Focusing only on scientific research without explaining translation toward clinical development. Tips for Applicants Before submitting an application, organisations should: - Confirm their Victorian eligibility. - Verify their ABN and organisational status. - Clearly define the mRNA vaccine or therapeutic candidate. - Explain the unmet health need. - Provide evidence supporting the scientific concept. - Demonstrate ownership or commercialisation rights for relevant IP. - Define the current and target Technology Readiness Levels. - Develop realistic technical milestones. - Address GMP manufacturing feasibility. - Explain the pathway toward Phase I clinical development. - Demonstrate co-funding or sufficient financial capacity. - Provide a clear commercialisation strategy. Key Facts at a Glance - Program: mRNA Victoria Pipeline Program – Round 1 - Location: Victoria, Australia - Maximum grant: $1 million - Focus: mRNA vaccines and therapeutics - Priority areas: Infectious diseases, emerging health threats, cancer, genetic disorders, rare diseases, and autoimmune diseases - Eligible applicants: Victorian-based eligible companies, incorporated associations, statutory corporations, universities, hospitals, TAFEs, and other qualifying organisations - ABN: Required - Victorian connection: Required - IP: Applicant must own or have rights to commercialise relevant IP - Manufacturing requirement: Project must be capable of manufacture at the BioNTech GMP Clinical Manufacturing Facility or R&D Production Laboratory - Development requirement: Project must be capable of reaching a higher TRL within three years - Co-funding: Required, or applicants must demonstrate sufficient financial capacity to complete the project beyond grant support - Long-term objective: Progression toward GMP manufacturing and Phase I clinical trials Frequently Asked Questions 1. What is the mRNA Victoria Pipeline Program? It is a funding program designed to support Victorian organisations developing innovative mRNA vaccines and therapeutics and help promising candidates progress toward clinical development and manufacturing. 2. How much funding is available? Eligible projects can receive grants of up to $1 million. 3. What types of mRNA products are supported? The program supports mRNA vaccines for infectious diseases and emerging health threats, as well as mRNA therapeutics targeting cancer, genetic disorders, rare diseases, and autoimmune diseases. 4. Who can apply? Eligible Victorian-based organisations can include companies registered under the Corporations Act 2001, Victorian incorporated associations, universities, hospitals, TAFEs, and other qualifying statutory corporations. 5. Does the applicant need to own the intellectual property? The applicant must hold the relevant IP or have appropriate rights to commercialise the relevant intellectual property. 6. What is the Technology Readiness Level requirement? The project must be capable of progressing to a higher Technology Readiness Level within three years. Applicants should clearly demonstrate how their proposed activities will achieve this progression. 7. Is co-funding required? Applicants must provide co-funding or demonstrate sufficient financial capacity to complete the project beyond the grant support. Conclusion The mRNA Victoria Pipeline Program – Round 1 provides up to $1 million to help Victorian organisations accelerate the development of innovative mRNA vaccines and therapeutics. The program supports activities ranging from pre-clinical proof of concept and safety testing to prototype production, regulatory preparation, commercialisation planning, specialist equipment, and commercialisation training. The strongest applications will demonstrate scientific innovation, clear intellectual property rights, Victorian capability, manufacturing feasibility, realistic Technology Readiness Level progression, and a credible pathway toward GMP manufacturing and Phase I clinical trials. By supporting the translation of promising mRNA research into clinical and commercial development, the program aims to strengthen Victoria’s sovereign mRNA capability, advanced medical research ecosystem, and biomanufacturing pipeline. For more information, visit Avant Group.